Post by
retiredcop on May 11, 2023 10:06am
PMN310 going in the right direction
Everyday more and more support seems to be coming out for targeting the oligomers in the treatment of AD. More public awareness just boosts PMN's direction and we will get alot more coverage when we start releasing data from our clinical trials. The timing is really working in our favour
https://neurosciencenews.com/amyloid-fibril-neuropharmacology-23207/
Comment by
M101 on May 11, 2023 11:16am
This is the one (only?) thing Goldstein got right: big pharma needed anything that could be made (paid) to look like a win that they could spin for years, given that they already controlled the other two cornerstones of market success, media and regulation. And spinning they are!